Kedrion Biopharma an important Share Purchase Agreement with Liminal BioSciences Inc. The agreement is for the purchase of Prometic Bioproduction Inc, a production plant in Québec (the "First Closing"), and Prometic Biotherapeutics Inc, which holds the biological license application for an FDA-approved drug to treat Plasminogen Deficiency type 1 (Hypoplasminogenemia), a rare systemic disease (the "Second Closing"). Crédit Agricole Corporate and Investment Bank, Intesa Sanpaolo S.p.A., Mediobanca - Banca di Credito Finanziario S.p.A., Natixis and UniCredit Bank AG served as joint bookrunners.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.52 EUR | +0.14% | -0.75% | +29.59% |
28/05 | Mediobanca to offer richer clients illiquid KKR alternative fund | RE |
27/05 | Sichel sold 7,645 shares of Mediobanca. | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.59% | 13.09B | |
+19.12% | 582B | |
+18.87% | 313B | |
+15.71% | 251B | |
+21.74% | 209B | |
+19.14% | 180B | |
+24.16% | 169B | |
+9.58% | 164B | |
+11.18% | 154B | |
-10.40% | 140B |
- Stock Market
- Equities
- MB Stock
- News Mediobanca S.p.A.
- Crédit Agricole Corporate and Investment Bank, Intesa Sanpaolo S.p.A., Mediobanca - Banca di Credito Finanziario S.p.A., Natixis and UniCredit Bank AG Serve as Joint Bookrunner